OTLK · Company research
Outlook Therapeutics, Inc. Common Stock (OTLK): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
16records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside - Stocktwits | OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside Stocktwits | View source ↗ | Stocktwits | Oct 18, 2026 | neutral | 0 | 0.6 |
| VAL,OTLK,JANX,INMB,VRDN,DELL,ASTS | Stock Prices | Quote Comparison - Yahoo! Finance Canada | VAL,OTLK,JANX,INMB,VRDN,DELL,ASTS | Stock Prices | Quote Comparison Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 17, 2026 | neutral | 0 | 0.6 |
| OTLK Stock Generates Buzz Ahead Of FDA Decision On Wet AMD Therapy – Retail Says Favorable Verdict Could Cause A ‘Big Boom’ - Stocktwits | OTLK Stock Generates Buzz Ahead Of FDA Decision On Wet AMD Therapy – Retail Says Favorable Verdict Could Cause A ‘Big Boom’ Stocktwits | View source ↗ | Stocktwits | Oct 16, 2026 | neutral | 0 | 0.6 |
| Two reported owners share voting power over a stake above 5% in Outlook Therapeutics (OTLK). - Stock Titan | Two reported owners share voting power over a stake above 5% in Outlook Therapeutics (OTLK). Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| OTLK Stock Surges After FDA Ends Decade-Long Wait For Ophthalmic Bevacizumab - Stocktwits | OTLK Stock Surges After FDA Ends Decade-Long Wait For Ophthalmic Bevacizumab Stocktwits | View source ↗ | Stocktwits | Oct 13, 2026 | neutral | 0 | 0.6 |
| OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision - Stocktwits | OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision Stocktwits | View source ↗ | Stocktwits | Oct 13, 2026 | neutral | 0 | 0.6 |
| These 3 Stocks Led Wall Street’s Biggest Gains On Tuesday – Here’s Why - Stocktwits | These 3 Stocks Led Wall Street’s Biggest Gains On Tuesday – Here’s Why Stocktwits | View source ↗ | Stocktwits | Oct 13, 2026 | neutral | 0 | 0.6 |
| Outlook Therapeutics (Nasdaq:OTLK) - Stock Analysis - Simply Wall Street | Outlook Therapeutics (Nasdaq:OTLK) - Stock Analysis Simply Wall Street | View source ↗ | Simply Wall Street | Oct 11, 2026 | neutral | 0 | 0.6 |
| Outlook Therapeutics hires a CFO for its only FDA-approved eye version of bevacizumab - Stock Titan | Outlook Therapeutics hires a CFO for its only FDA-approved eye version of bevacizumab Stock Titan | View source ↗ | Stock Titan | Aug 27, 2026 | neutral | 0 | 0.6 |
| Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet - Yahoo Finance | Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet Yahoo Finance | View source ↗ | Yahoo Finance | Aug 15, 2026 | neutral | 0 | 0.6 |
| Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance | Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Aug 14, 2026 | neutral | 0 | 0.6 |
| OTLK Up More Than 300% in 3 Months: Here's What You Should Know - Yahoo Finance | OTLK Up More Than 300% in 3 Months: Here's What You Should Know Yahoo Finance | View source ↗ | Yahoo Finance | Aug 10, 2026 | neutral | 0 | 0.6 |
| Outlook Therapeutics Stock (OTLK) Opinions on FDA Approval of LYTENAVA - Quiver Quantitative | Outlook Therapeutics Stock (OTLK) Opinions on FDA Approval of LYTENAVA Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 5, 2026 | neutral | 0 | 0.6 |
| OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside - TradingView | OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside TradingView | View source ↗ | TradingView | Jul 27, 2026 | neutral | 0 | 0.6 |
| Outlook Therapeutics Stock (OTLK) Opinions on FDA Review for Lytenava - Quiver Quantitative | Outlook Therapeutics Stock (OTLK) Opinions on FDA Review for Lytenava Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 1, 2026 | neutral | 0 | 0.6 |
| Outlook Therapeutics (OTLK) Stock After FDA Review Win Is The Valuation Case Already Priced In - Yahoo Finance | Outlook Therapeutics (OTLK) Stock After FDA Review Win Is The Valuation Case Already Priced In Yahoo Finance | View source ↗ | Yahoo Finance | Jun 16, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.